Every round on record, with the sources behind each and the investors on them.
A clinical-stage biotechnology company that uses AI to discover medicines from life's chemistry
enveda.comLinkedInBoulder, ColoradoBiotechFounded 2019201-500 people
| Round | Amount | Announced | Lead | Verified | Status | Sources |
|---|---|---|---|---|---|---|
| Series D+ series E | $311M | 2026-09-23 | Catalio Capital Management | 6 | [ PUBLISHED ] | 11 |
[ VERIFIED ]1.00 read against 6 sources
[ BUILT WITH ]·[ SEARCH ]found by Firecrawl search: "late-stage" funding round raises million· | ||||||
Enveda builds AI-powered tools that read life's chemistry to discover and develop small-molecule medicines for patients with serious diseases.
| Round | Amount | Announced | Lead |
|---|---|---|---|
| Seed | $4.9 million | undated | True Ventures |
| Series A | $51M | 2021-06-22 | Lux Capital |
| Series B | $68-million | 2022-12-21 | Dimension |
| Series B1 | $51 million | 2023-04-20 | Kinnevik |
| Series B2 | $55 million | 2024-06-14 | not stated |
| Series C | $130 million | 2024-11-21 | Kinnevik, FPV |
| Series C closing | $150 million | 2025-02 | not stated |
| Series D | $150 million | 2025-09-04 | Premji Invest |
Enveda is tackling the slow, expensive work of identifying and characterizing molecules in nature by combining mass spectrometry, machine learning, and automated experiments, and says its platform has produced 17 development candidates, three of which are in human trials. The latest financing is intended to move three clinical-stage medicines into later-stage development and bring additional inflammatory and metabolic medicines into trials, making the bet that AI can turn previously inaccessible life chemistry into a repeatable pipeline of medicines.
Via Alexandria from FullEnrich: founded, headcount, type, industry
Catalio Capital Management
Baillie Gifford
Digitalis Ventures
Dimension
Durable Capital Partners
FPV Ventures
Iconiq
Kinnevik
Lifeforce Capital
Lightspeed
Lux Capital
Premji Invest
True Ventures